mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival

• Published in: International journal of clinical oncology Vol. 24; no. 5; pp. 516 - 525
• Main Authors: Yasuno, Masamichi, Uetake, Hiroyuki, Ishiguro, Megumi, Mizunuma, Nobuyuki, Komori, Takamichi, Miyata, Go, Shiomi, Akio, Kagimura, Tatsuo, Sugihara, Kenichi
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.05.2019; Springer Nature B.V
• Subjects: Bevacizumab; Cancer Research; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Hepatectomy; Immunotherapy; Liver; Medicine; Medicine & Public Health; Metastases; Metastasis; Monoclonal antibodies; Oncology; Original; Original Article; Surgical Oncology; Survival; Targeted cancer therapy; Tumors; Initially resectable; Initially unresectable; Liver metastases; Colorectal cancer; Hepatectomy
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-018-01393-8

Background The TRICC0808 trial is a phase II multi-institutional trial that investigated the efficacy of preoperative mFOLFOX6 + bevacizumab (BV) therapy for liver-only metastasis that is unsuitable for upfront resection. The R0 resection rate in the efficacy analysis has been reported to be 44.4%, and the final analysis for survival was conducted (data fixation on February 16, 2015). Methods Six cycles of mFOLFOX6 + BV therapy were applied to patients with liver-only metastases, which were > 5 cm in diameter or more than four tumors (H2 and H3), and hepatectomy was performed if possible. Primary and secondary endpoints were the R0 hepatectomy rate and overall survival (OS), respectively. Results Of 46 patients registered, OS was analyzed for 45 patients in whom the 3-year OS rate from the starting date of chemotherapy was 44.0% with a 33.6-month median survival time (MST). The 3-year OS rate of 31 patients with hepatectomy, including resection after an additional chemotherapy, was 61.3% with a 43.1-month MST, which was significantly better than 0% of the 3-year OS rate with a 21.0-month MST of 14 patients without hepatectomy ( p value < 0.0001). In 24 patients who underwent hepatectomy after six cycles of protocol chemotherapy, the 3-year relapse-free survival rate was 8.3%, with a 36.8-month MST. Conclusions This final analysis of the TRICC0808 trial revealed a better long-term survival in patients with hepatectomy after mFOLFOX6 + BV therapy, although most examined patients eventually developed recurrence. Thus, hepatectomy after chemotherapy might improve the survival in patients with advanced liver metastases, although cure remains difficult.